Carl Zeiss Meditec acquires shareholding in WaveLight AG
Jena, 03 August 2007 - Medical technology provider Carl Zeiss Meditec
AG (ISIN DE0005313704), listed on TecDAX of the German Stock
Exchange, published the acquisition of 5% shareholding in Wavelight.
"At this point in time the acquisition of stock demonstrates that we
have an interest in WaveLight in principle", said Jens Brajer,
Director Investor Relations at Carl Zeiss Meditec AG. "We are
currently evaluating the option of a voluntary takeover offer. This
is based on the expectations regarding the future earning potential
of WaveLight and potential synergies from business combination."
Brief profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world's
leading medical technology companies. This market position is based
on over 160 years of experience in optical innovation.
The company has two primary areas of activity: In the field of
ophthalmology Carl Zeiss Meditec offers integrated solutions for
treating the four main eye ailments: vision defects (refraction),
cataracts, glaucomas and retinal disorders. The company's system
solutions are employed in all phases of the disease management, from
diagnosis to treatment and aftercare. Carl Zeiss Meditec has always
applied its technological expertise to product innovations. These
innovations range from basic systems such as slit lamps and fundus
cameras to standard setting diagnostic systems such as the Humphrey®
Field Analyser, the Stratus OCT(TM) and the IOLMaster®, through to
the surgical microscopes and innovative treatment systems in
refractive laser surgery. The product portfolio in ophthalmic surgery
is rounded off by intraocular lenses and consumables.
In the field of neuro and ENT surgery, Carl Zeiss Meditec is the
world's leading provider of surgical microscopes and microsurgical
visualisation solutions for a very broad range of applications, such
as tumor and vascular surgery in the head region and/or spinal
surgery. The most recent example of our innovative performance in
the area of microsurgery is the OPMI Pentero® visualisation system,
which allows efficient and ergonomic patient treatment and runs
counter to the increasing costs of healthcare. Carl Zeiss Meditec
will systematically expand its product range in this area and become
a solution provider in neuro and ENT surgery as well.
Carl Zeiss Meditec's medical technology portfolio is rounded off by
visualisation systems for doctors in private practice and promising
future technologies such as intraoperative radiation therapy, which
allows the targeted treatment of breast cancer and brain cancer
during the operation stage itself.
The increasingly aging global population, rising expectations of
doctors and patients, together with innovative treatment methods in
medical technology are expected to promote market growth in the long
term. Carl Zeiss Meditec holds an optimum position for future
developments in the health sector. The company focuses its solution
portfolio on the three medical challenges with a significant social
and economic impact: loss of mobility, vision and cognitive
abilities. The goal is to deliver technologies and
application-oriented solutions that allow doctors to improve the
quality of life of their patients and to further improve the
efficiency of diagnosis and treatment.
Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in
Germany (Carl Zeiss Meditec Surgical GmbH and Carl Zeiss Meditec
Vertriebsgesellschaf mbH), the USA (Carl Zeiss Meditec, Inc., Dublin
California), in Japan (Carl Zeiss Meditec Co., Ltd., Tokyo), Spain
(Carl Zeiss Meditec Iberia S.A., Madrid) and France (Ioltech SAS, La
Rochelle, and Carl Zeiss Meditec France SAS, Le Pecq).
Thirty-five percent of the Carl Zeiss Meditec shares are in free
float. The remaining 65 percent are held by Carl Zeiss, one of the
world's leading international groups engaged in the optical and
opto-electronics industry.
Contact
Jens Brajer/Director Investor Relations
Göschwitzer Straße 51-52
07745 Jena
Phone: +49 (0) 36 41 - 2 20 - 1 05
Fax: +49 (0) 36 41 - 2 20 - 1 17
E-Mail: investors@meditec.zeiss.com
Web: http://www.meditec.zeiss.com
--- End of Message ---
Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany
WKN:
531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share,
TecDAX;
Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Stuttgart,
Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Düsseldorf,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse, Geregelter Markt in
Frankfurter Wertpapierbörse;